Expert Discusses Positive Outcomes Associated With Oncology Care Model
February 4th 2022Stuart Staggs, senior director of strategic programs at McKesson, discussed the encouraging metrics associated with use of the Oncology Care Model (OCM) sponsored by the Centers for Medicare and Medicaid Services.
Expert Discusses Logistics Behind the Mark Cuban Cost Plus Drug Company
February 4th 2022Ned Milenkovich, PharmD, JD, licensed pharmacist and principal at Much Law, PC, discusses the announcement of the Mark Cuban Cost Plus Drug Company, which will, in some cases, offer expensive medication at a drastically lower price without insurance.
Expert: Cancer Screening Rates in 2021 Remain Lower Than Expected
February 2nd 2022Christopher Mast, MD, vice president of clinical informatics at Epic, discusses research that showed that cancer screening rates in 2021 rebounded from the low rates at the start of the pandemic, but not significantly.
Pharmacy Technicians Initially Hesitant About Administering Vaccines
January 31st 2022Ashley Woodyard, a PharmD candidate at the Touro University California College of Pharmacy in Vallejo and co-author of an article in the January 2022 issue of Pharmacy Times®, discussed the article and the benefits of pharmacy technicians as vaccine administrators.
Practice Pearl 3: Reducing Costs of PARPi for Ovarian Cancer Treatment
January 28th 2022Experts in gynecologic oncology provide insight on available patient assistance programs to help lower costs of PARP inhibitors for the treatment of ovarian cancer, and how pharmacists can aid in obtaining this information.
ASHP Discusses Grant Received From American Rescue Plan
January 28th 2022Anna Legreid Dopp, PharmD, the Senior Director of Clinical Guidelines & Quality Improvement at ASHP, and Bayli Larson, PharmD, the Strategic Initiatives Associate at ASHP, discuss the grant the ASHP received from the American Rescue Plan.
Pharmacist Medication Insights: Abemaciclib (Verzenio) for Breast Cancer
January 28th 2022Abemaciclib (Verzenio) was recently approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.
Expert: Mark Cuban Cost Plus Drug Company Raises Questions, But May Not Be Cause for Concern
January 27th 2022Ron Lanton III, Esq, principal at Lanton Law, said entrepreneur Mark Cuban's new venture into the pharmacy field is very interesting, although it maybe just another player in the mail-order pharmacy market.
Survey Shows Pharmacy Teams Continue to Be Stretched Thin During Pandemic
January 27th 2022Mitchel Rothholz, RPh, MBA, chief of governance and state affiliates at the American Pharmacists Association (APhA) and executive director of the APhA Foundation, discusses the results of a nationwide survey of pharmacists during the ongoing pandemic.
Trends in the ASCVD, LDL-C Management Treatment Landscape in 2022
January 27th 2022Norman Lepor, MD, a cardiologist and clinical investigator in the phase 3 clinical program for inclisiran (Leqvio; Novartis), discusses major trends in the atherosclerotic cardiovascular disease and LDL-C management treatment landscape this year.
The Shifting Health Care Landscape for Pharmacy Technicians
January 27th 2022Expert panel discusses the current state of the pharmacy technician role, how COVID-19 changed the perception of pharmacy technicians, and updates across the legislative and regulatory landscape for pharmacy technician–administered tests and vaccines.